Acceptance And Commitment Therapy For Medication-resistant Psychosis: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$558,200.00
Summary
In spite of advances in medication, approximately one third of people with schizophrenia continue to experience distressing symptoms such as hearing voices and paranoia. Psychological 'talking treatments' are effective in helping people to cope with and be less distressed by these experiences. This study will be the first trial of a new psychological treatment, called Acceptance and Commitment Therapy, which may be more effective, briefer and more easily provided than existing approaches.
Implementation And Sustainability Of Non-surgical Intervention For Dental Caries In General Dental Practice
Funder
National Health and Medical Research Council
Funding Amount
$390,388.00
Summary
Dentists in NSW and the ACT used new protocols to stop the spread of tooth decay. Many decayed teeth were then remineralised without the use of injections or drilling and filling. The process by which the dentists reorganised their practices to implement the protocols and how they explained them to their patients and practice staff will now be investigated to discover how best to promote their use Australia-wide. The sustainability and cost-effectiveness of this type of care will be measured.
Therapeutic Targeting Of MYCN Oncoprotein Stability In Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$590,206.00
Summary
A high level of MYCN protein is a major indicator of aggressive neuroblastoma (NB) but unfortunately there have been many barriers to the design of targeted therapies. We have identified a protein called PA2G4 which is a cofactor for MYCN in promoting cancer cell growth. We have developed a compound which inhibits PA2G4 and MYCN protein levels and reduces tumour growth. We will examine how PA2G4 cause aggressive tumour characteristics and test new methods to block PA2G4.
There is an unmet medical need to develop new therapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoints TIGIT and CD96 represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. PD1/PD-L1). While testing these as targets in mice we will also learn more about their ligand CD155 and their expression in human tumors.
Engineered Cell And Exosome Therapy For Pulmonary Vascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$838,490.00
Summary
Diseases affecting the blood vessels in the lungs cause early death and the currently available treatments are not curative. We will take advantage of the latest developments in the understanding of the molecular basis of these diseases to design and test a new treatment approach using cells and cell-derived products as a therapy.
Overcoming Receptor Tyrosine Kinase Mediated Resistance To BRAF Inhibitors In Metastatic Melanoma, Colorectal And Lung Cancers.
Funder
National Health and Medical Research Council
Funding Amount
$574,958.00
Summary
The drug Vemurafenib results in good responses in melanoma patients. However, patients become resistant to treatment. We have identified specific receptors that can cause Vemurafenib resistance, which can be overcome by combination treatment with drugs to these receptors. We will assess melanoma patient samples for expression of these receptors which will be highly beneficial for selecting combination treatments to prevent drug resistance and ensure better prolonged outcomes.
Design And Application Of New Nanomaterials Theranostic Platforms For Targeted Treatment Of Cancer
Funder
National Health and Medical Research Council
Funding Amount
$530,626.00
Summary
The project aims to develop intelligent drugs that attract to malignant tumors like magnets. These powerful, next-generation chemotherapy drugs seek out cancerous cells, allowing physicians to see exactly where tumours lie. Nanoparticles inside the drugs then switch on upon contact with X-ray radiation beams. This new method, which can diagnose, deliver targeted therapy and monitor the response to therapy all at the same time, would reduce the amount of radiation needed to kill cancer cells.
Developing Irreversible Electroporation Non-Thermal Tumor Ablation For Organ-Confined Prostate Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$290,512.00
Summary
IRE is technique for targeted tissue ablation. Electrodes placed into the targeted area deliver intense, brief electric pulses. Nano-scale pores are created in the cell membrane killing the cells but preserving the extracellular matrix. The pulses do not affect sensitive structures including neurovascular bundles, major vasculature and ductal systems preserving their function. It may address prostate regions implicated in prostate cancer without damaging vital structures, reducing side effects.
A New And Effective Approach To Reversal Of Allergic Airways Inflammation By Turning Off Allergic Responses
Funder
National Health and Medical Research Council
Funding Amount
$393,514.00
Summary
Inflammatory diseases like asthma develop from misdirected immune responses. The ultimate goal of therapeutic strategies is to remove or inactivate the cells that cause inflammation while leaving other cells, for example, those required for protection from infectious diseases and tumours, unaffected. Here we propose to test a new way of turning off the inappropriate immune reaction with the goal of preventing or reversing asthma.
A Novel, Technology-based Program Targeting Physical, Cognitive And Mental Well-being To Maximise Fall Prevention In Older People: An Evidence-based Multifactorial Approach
Funder
National Health and Medical Research Council
Funding Amount
$1,475,781.00
Summary
Accidental falling among older people is a significant public health challenge worldwide. This study addresses a key gap in the translation of available evidence to prevent falls in older people more effectively. The proposed trial will provide the first-ever evidence about the cost and effectiveness of a tailored multifactorial fall prevention program using technology and self-management principles.